Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Three new cancer treatments are to be made available on the NHS in Scotland, as six drugs are given the green light for use.

Six new drugs, including a treatment for patients with advanced breast cancer, have been approved for use by the NHS in ...

If confirmed on larger case studies, the results of this study suggest that samples for Tg/CT mRNA and Tg protein measurements from CLN suspicious for metastatic thyroid cancer should be always ...

Precigen has a market cap of $468mn and a cash runway into 2026, but needs more funds for commercialization. Check out my ...

as a monotherapy for the treatment of adult patients with second-line recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy. The approval means ...

The Obafemi Awolowo University Teaching Hospital Complex (OAUTHC), Ile-Ife, performed 55 cancer surgeries in January, according to Prof. Segun Alatise, a professor of surgery in the hospital’s ...

Today, on World Cancer Day, we come together to raise awareness, promote early detection and encourage prevention.

The cost of diagnosis of cancer, which can go up to Rs 50,000-60,000 is not included in the health insurance policies ...

Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and Merck’s KEYTRUDA® ...

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for ...